

UniQuest — Technology Transfer Company of The University of Queensland

City Innovation Library · Good practice · Australia

Quality score: 62/100

Evidence strength: Moderate

Summary

UniQuest, University of Queensland's tech-transfer firm since 1984, licensed the Gardasil HPV-vaccine IP and creates spin-outs. Audited UQ accounts confirm rising Gardasil royalties; UniQuest reports 141 spin-outs, though only 46% stayed active or exited well.

Key dimensions

Dimension	Score
Evidence of impact / measured results	3/3
Transferability / demonstrated replication	2/3
Scalability	2/3
Sustainability / continuity	3/3
Innovation	1/3
Inclusiveness / equity	0/3
Multi-stakeholder collaboration	2/3

Evaluated by C-NAPSE

Data sources

[C-NAPSE web research](#) — accessed 2026-07-23

[UniQuest Pty Limited \(The University of Queensland\)](#) — accessed 2026-07-23

[UniQuest — Our impact in numbers](#) — accessed 2026-07-23

[Times Higher Education: Australia's spin-out success](#) — accessed 2026-07-23

[Global University Venturing: equity demands at Australasian universities](#) — accessed 2026-07-23

[UQ Annual Report 2021 — audited financials \(PDF\)](#) — accessed 2026-07-23

Cite this — Evidoria. *UniQuest — Technology Transfer Company of The University of Queensland*. Persistent ID: a5b6c15d-788f-4fd9-a2dd-2c593e1d9e8f.